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Abstract (292 words) 
Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide, and 
has emerged as a critical risk factor for multiple neurodegenerative diseases, particularly 
Alzheimer’s disease (AD). How the inflammatory cascade resulting from mechanical stress, 
axonal shearing and the loss of neurons and glia following initial impact in TBI, contributes to 
the development of AD-like disease is unclear. Neuroinflammation, characterized by blood-brain 
barrier (BBB) dysfunction and activation of brain-resident microglia and astrocytes, resulting in 
secretion of inflammatory mediators and subsequent recruitment of peripheral immune cells has 
been the focus of extensive research in attempts to identify drug-targets towards improving 
functional outcomes post TBI. While knowledge of intricate cellular interactions that shape 
lesion pathophysiology is incomplete, a major limitation in the field is the lack of understanding 
of how distinct cell types differentially alter TBI pathology. The aim of this review is to 
highlight functional differences between populations of bone marrow derived, infiltrating 
monocytes/macrophages and brain-resident microglia based on differential expression of the 
chemokine receptors CCR2 and CX3CR1. This review will focus on how unique subsets of 
mononuclear phagocytes shape TBI pathophysiology, neurotoxicity and BBB function, in a 
disease-stage dependent manner. Additionally, this review summarizes the role of multiple 
microglia and macrophage receptors, namely CCR2, CX3CR1 and Triggering Receptor 
Expressed on Myeloid Cells-2 (TREM2) in pathological neuroinflammation and 
neurodegeneration vs. recovery following TBI. TREM2 has been implicated in mediating AD-
related pathology, and variants in TREM2 are particularly important due to their correlation with 
exacerbated neurodegeneration. Finally, this review highlights behavioral outcomes associated 
with microglial vs. macrophage variances, the need for novel treatment strategies that target 
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unique subpopulations of peripheral macrophages, and the importance of development of 
therapeutics to modulate inflammatory functions of brain-resident microglia at specific stages of 
TBI. 
Keywords: Traumatic Brain Injury, Alzheimer’s disease, Neuroinflammation, 
Neurodegeneration, Blood-brain barrier, Microglia, Macrophages, Astrocytes, TREM2  
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1. Introduction. 
Traumatic Brain Injury (TBI) is defined by The Centers for Disease Control and 
Prevention (CDC) as the functional disruption of the brain from an impact or penetrating injury 
(1)
, resulting in apoptotic and necrotic cell death of neurons and glia, disruption of the blood-
brain barrier (BBB) with subsequent infiltration of the injured brain by peripherally-derived, 
immune cell populations such as neutrophils and macrophages. This is accompanied by 
phenotypic activation of brain-resident glia, namely astrocytes and microglia
 (2-4)
. Approximately 
10 million people experience some form of TBI every year 
(5)
. In the United States, 1.4 million 
people suffer from TBI each year, with approximately 235,000 patients requiring hospitalization 
and specialized healthcare. Strikingly, TBI accounts for approximately 50,000 mortalities each 
year, along with over 90,000 individuals facing a lifetime of permanent post-injury impairment 
(1)
. Post-injury disabilities can encompass a myriad of cognitive, motor, and emotional deficits 
and result in healthcare costs that range into the upper millions to billions of dollars.  Of 
particular importance is the fact that TBI has been identified as a significant risk factor for the 
development of Alzheimer’s disease (AD) related pathological changes including intra-neuronal 
neurofibrillary tangles (NFTs) of hyperphosphorylated tau (pTau) and deposits of extracellular 
amyloid-β (Aβ) (6). It is important to note that single occurrence brain injuries are predominantly 
associated with AD, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS), while 
Chronic Traumatic Encephalopathy (CTE) is the most prevalent disease associated with 
repetitive TBI. Given the increasing prevalence of AD worldwide, and that it is currently 
classified as the most common form of dementia, this review will focus on the development of 
AD/AD-like pathology following single occurrence TBI. Although there is a growing need to 
understand disease mechanisms resulting in CTE, these remain beyond the scope of this review.  
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While mechanisms that govern the pathophysiology of TBI lesions and result in AD-like 
neurodegenerative changes are poorly understood, increasing experimental and clinical data 
implicate chronic post-injury neuroinflammation as a potential catalyst for TBI-related 
neurodegeneration and cognitive decline. The lack of a clear understanding of the complexity of 
the inflammatory response following TBI has been a significant hindrance to the development of 
successful therapeutics to minimize and/or ameliorate post-injury deficits. The unique 
pathological and inflammatory features of TBI vary based on the severity (mild vs. moderate vs. 
severe) and duration (single vs. repetitive) of the injury 
(2-4)
. This, in combination with the 
evolving nature of TBI lesions as injury becomes chronic, has added to the dilemma of failed 
treatment paradigms. Lastly, extensive research has been dedicated towards development of anti-
inflammatory drugs targeting functional responses of immune cell populations, namely the blood 
derived macrophages and the brain-resident microglia. However, an incomplete understanding of 
their unique contributions to TBI pathogenesis in a disease-stage dependent manner has led to 
several failed clinical trials and ineffective treatment strategies 
(7)
. This review seeks to outline 
what is currently known about cellular mechanisms that shape inflammatory responses post 
moderate to severe single occurrence TBI, with a particular focus on defining functional 
differences between activated peripheral macrophage populations and brain-resident microglia, 
and how they relate to development of AD-like, neurodegenerative pathology post TBI. 
1.1. The problem with ‘immune privilege’ in TBI. 
The central nervous system (CNS), composed of terminally differentiated neurons and 
highly specialized glial cells, the astrocytes, microglia and oligodendrocytes, comprises a unique 
neuro-immunologic niche. Complex interactions between various populations of glia and 
neurons are critical for the functional integrity of the CNS. Based on homeostatic mechanisms 
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involving critical immune interactions evolved to limit immune-mediated damage and loss of 
CNS function, the CNS is considered 'immunologically privileged’ where responses with a 
potential to cause bystander injury to healthy tissue are selectively restricted and those that 
promote repair and homeostasis are preserved and/or enhanced 
(8,9)
.  
Specialized draining lymphatics and the recently discovered, glial-dependent glymphatic 
system that allow for controlled cellular and molecular egress into the deep cervical lymph nodes 
(9,10)
, and limited cellular expression of major histocompatibility complex (MHC) molecules limit 
endogenous antigen presentation 
(8,9)
. Constitutive expression of soluble immune-suppressive 
factors like TGFβ, macrophage migratory inhibition factor (MIF) and neurotrophins results in 
tolerance-inducing antigen presenting cells (APCs) leading to overall T-cell suppression and 
inhibition of Natural Killer (NK) cell-mediated cytolysis. Furthermore, bi-directional signaling 
between neurons and microglia via fractalkine (CX3CL1), CD200 and neurotransmitter signaling 
actively maintains microglia in their homeostatic activation state 
(11)
. Finally, blood vessels lining 
the CNS are composed of specialized endothelial cells with restricted expression of adhesion 
molecules and presence of tight junction proteins that act to restrict the access of large molecules 
and peripheral immune cells 
(3,12)
. The basement membrane separates the endothelium from the 
brain parenchyma, and is juxtaposed with pericytes, astrocytic endfeet and microglia. This 
neurovascular unit is collectively called the ‘blood-brain barrier (BBB)’ and is the final, 
important factor in CNS immune privilege 
(12)
. 
This neurological milieu presents a unique challenge following trauma or injury. Pro-
inflammatory immune signaling is critical for the resolution and containment of pathogens, but 
also causes bystander, immune-mediated cell death. Although heightened anti-inflammatory 
responses can minimize bystander damage, early inhibition of inflammation can lead to chronic 
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pathology and lesion spread. Thus, the CNS immune response has to be finely tailored to a) 
allow for a controlled pro-inflammatory response that effectively resolves initial pathology and 
limits the expansion of injury lesions into surrounding, uninjured tissue and b) mount a well-
timed anti-inflammatory response that facilitates repair mechanisms without resulting in the 
persistence of the initial injury. 
1.2. Injury Mechanisms in TBI: The ‘double edged sword’ of neuroinflammation. 
Pathology following brain trauma is an evolving continuum of two phases of injury. 
Primary pathology that manifests as neuronal and glial cell death, axonal shearing/injury, edema 
and disruption of the BBB is a direct consequence of physical and mechanical impact on the 
brain. Cellular death results in the release of DNA, RNA, ATP, reactive oxygen species (ROS) 
and necrotic cellular debris 
(2-4)
. These ‘damage associated molecular patterns’ (DAMPs), via 
signaling through pattern recognition receptors (PRRs) and Toll like receptors (TLRs) trigger 
activation of the resident immune cells of the brain, namely the microglia and astrocytes, and 
initiate the first wave of neuroinflammation (Fig 1). This involves inflammasome-activation and 
release of cytokines (TNF, IFNγ, IL-1β, IL-10), chemokines (CCL2, CCL5, CXCL9) and 
inflammatory mediators (GM-CSF, Type-I Interferon, complement proteins, Nitric Oxide), that 
further coordinate the recruitment, expansion and survival of peripheral immune cells such as the 
macrophages, dendritic cells, T cells and B cells within the injured tissue 
(2-4,13)
. Gliosis 
associated with the injury serves to segregate the lesioned region from the surrounding healthy 
tissue and thereby prevents pro-inflammatory cytokine and ROS mediated bystander cell death 
(2,3)
. Additionally, studies of traumatic spinal cord injury (SCI) have demonstrated that lesion-
associated reactive astrocytes and microglia secrete BDNF, TGF , and FGF2 that promote 
neuronal survival and recruitment and differentiation of oligodendrocyte progenitor cells (OPCs) 
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(14)
. Thus, the acute inflammatory response creates an environment conducive for tissue repair by 
promoting efficient clearance of cellular debris and effective regenerative/repair promoting cell 
activation (Fig 1). 
Although necessary for initiation of active repair, the dysregulation of the acute immune 
response results in enhanced and sustained inflammation and subsequent, secondary, immune-
mediated tissue damage. Chronic microglial activation and persistent production of pro-
inflammatory mediators like ROS, IFNγ, IL-1β, and complement protein C1qa result in neuronal 
cell death.  Microglial derived pro-inflammatory mediators such as IL1-α, TNF and C1qa can 
alter astroglial activation and skew them towards a highly neurotoxic A1 phenotype (Fig.1) 
which is characterized by enhanced expression of complement component 3 (C3) 
(15)
. 
Additionally, these astrocytes are impaired in their ability to engulf synapses, leading to defects 
in synaptic pruning and synapse elimination
 (15)
. Lastly, the ‘glial scar’, composed of glial cells 
such as astrocytes and NG2 glia, along with pericytes and meningeal cells, surrounds the primary 
injury lesion and represents a molecular and physical barrier that inhibits transected axons from 
regenerating beyond the fibrotic tissue 
(2,3)
. The cognitive and neurological deficits that persist 
for years following initial injury have largely been attributed to this chronic pro-inflammatory 
response impeding axonal growth/regeneration. 
2. BBB dysfunction following TBI.  
The BBB is a selective barrier formed by cerebral microvascular endothelial cells and 
offers physical, transport, and metabolic protection to the brain. Tight junctions between 
endothelial cells form a physical barrier that selectively limits the transport of molecules and 
prevents entry of plasma proteins and peripheral antigens into the brain 
(3,12)
. However, various 
small molecules (e.g., O2 and CO2) and lipophilic agents can diffuse through the lipid membrane. 
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In addition, a transport barrier is formed by specific systems on the luminal and abluminal 
membranes, which regulate transcellular movement and endocytosis 
(16)
. As a result, large 
hydrophilic peptides and proteins, including cells of the peripheral immune system, are unable to 
cross the BBB unless they engage in a specific receptor-mediated transcytosis. Finally, various 
intra- and extra-cellular enzymes such as peptidases, nucleotidases, and monoamine oxidases 
that have the ability to inactivate neurotoxic compounds form a metabolic barrier. Thus, the BBB 
provides both passive and active protection to the brain, which can be significantly compromised 
following TBI 
(3,12)
.  
Ultimately, the BBB serves as a mechanism by which essential nutrients are allowed 
access to the brain while simultaneously mediating the clearance of waste or cellular debris from 
the CNS, thereby actively maintaining a homeostatic equilibrium. By restricting ionic and fluid 
movement between the blood and brain, the BBB assists in creating an optimal environment for 
neuronal functioning. The BBB also acts as a barrier between neurotransmitters and other 
lipophilic agents that are active in the CNS, and peripheral tissue, thereby limiting crosstalk 
between the two systems in a healthy state 
(3,12)
. Consequently, disruption or damage to the BBB 
can hamper barrier protection and jeopardize brain homeostasis. In the case of TBI, post-injury 
BBB dysfunction can be biphasic 
(17)
 and occur as a direct result of the primary injury or as a 
delayed consequence of sustained inflammatory and cellular responses associated with the 
primary injury 
(2,3)
. Influx of plasma proteins into the CNS through a damaged BBB following 
TBI is sufficient to induce a neuroinflammatory response (Fig.1).  Subsequent post-injury edema 
and increased intracranial pressure facilitate secondary injury cascades that affect all elements of 
the neurovascular unit, including neurons, astrocytes, pericytes, and microglia 
(2-4)
. Increased 
production of free radicals and cytokines as well as matrix metalloproteinases (MMPs) such as 
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MMP2, MMP3 and MMP9 increase BBB permeability and promote activation of local 
astrocytes and microglia (Fig.1) 
(3,12)
. The long-term consequence of this acute inflammatory 
response is largely dependent on the brain’s ability to reorganize and reestablish homeostasis. As 
a result, mild to moderate TBI may result in BBB dysfunction characterized by a transient 
opening of endothelial tight junctions resulting in a temporary influx of inflammatory molecules 
and immune cells from the periphery. Conversely, severe or repetitive TBI can result in a chronic 
breakdown of BBB function with subsequent long-term inflammatory consequences in the brain 
(2-4)
. 
Increasing evidence supports the notion that microglial activation impairs BBB function. 
First, microglial production of MMP2, MMP3, and MMP9 disrupts proteins in the basal lamina 
and degrades tight junctions following TBI 
(17)
. Second, experimental models have shown that 
reactive microglia produce oxygen free radicals and their reaction products, namely hydrogen 
peroxide and NO, facilitate oxidative damage and neurodegeneration 
(2,3,12)
. Consequently, this 
oxidative stress increases the permeability of endothelial cells, heightens expression of cell-
adhesion molecules and enhances immune cell infiltration 
(18)
. By contrast, recent experimental 
studies revealed that juxtavascular microglial cells are critical in mediating rapid closure/repair 
of small leaks in the BBB 
(19)
. Specifically, movement of microglial processes in response to 
small openings in the BBB is essential in determining how quickly the leaks are resolved. This 
physical barrier, in addition to potential trophic factors released from microglia, lend support to 
the notion that microglia are integral to the neurovascular unit and facilitate structural integrity of 
the BBB 
(12.19)
. Thus in the context of TBI, brain injury induced microglial reactivity or 
microglial damage may significantly impair the cell’s ability to appropriately respond to BBB 
disruption and support structural recovery from the primary insult. Signaling at the BBB can 
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potentially actively shape pathological changes occurring at the lesion-site following TBI. How 
these various cells and inflammatory mediators shape the function of the BBB post TBI, and 
whether the severity of TBI can skew astroglial and/or microglial responses towards 
exacerbating or repairing BBB dysfunction is still not completely understood (Fig.1). 
 
3. Cellular Responses in TBI: Microglia vs. Macrophages. 
Although elaborate cellular interactions are implicated in TBI pathology, activation of 
CNS resident microglia and subsequent recruitment of inflammatory macrophages constitute the 
majority of the immune response within 48-72 hours of TBI (Fig.1). Additionally, while the 
peripheral immune response subsides by 2-3 weeks, the lesion-associated activation of 
microglia/macrophages persists for months to years following initial injury 
(2,3)
. Thus, 
dysregulated acute activation of microglia and macrophages can not only exacerbate lesion 
pathology, but can also result in chronic bystander tissue damage. The experimental ablation of 
CD11b-expressing macrophage populations has been employed to understand their functional 
contributions to pathophysiology of TBI lesions, but have proven to be inconclusive. This is 
likely to be due to the depletion of both CD11b-expressing microglia along with infiltrating 
peripheral macrophages, thereby making it difficult to attribute the unaltered axonal injury and 
lesion volume to their differential neurotoxic and/or neuroprotective functions 
(2)
. Additionally, 
the ablation requires the systemic administration of drugs, which act to deplete all CD11b
+
 
populations including monocytes, macrophages and dendritic-cell subsets. This creates a 
heightened peripheral inflammatory milieu that may further influence the acute immune response 
post TBI. Moreover, while acute depletion of CD11b cells before TBI skews the CNS towards a 
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pro-inflammatory state, these studies showed that the drugs used to deplete the CD11b cells in 
the murine models themselves exerted neurotoxic effects that were independent of the injury 
(2)
.   
    Several gene expression studies have attributed distinct genetic signatures to CNS 
resident microglia and peripherally derived macrophages under homoeostatic and 
inflammatory/neurodegenerative conditions. There has been an increasing interest in 
understanding how resident microglia and infiltrating monocytes/macrophages may differentially 
modulate TBI lesions.  Based on their surface expression of the chemokine receptors CCR2 and 
CX3CR1, various subsets of bone marrow and yolk sac derived myeloid populations have been 
identified in rodent models of disease 
(20)
. In peripheral blood, two distinct monocyte subsets 
express distinct profiles of CX3CR1 and CCR2. CCR2
high
 CX3CR1
low/int 
Ly6c
high
 monocytes are 
the inflammatory subset that enters target tissues in response to injury and differentiates into 
inflammatory macrophages. In contrast, the CCR2
+
 CX3CR1
hi
 Ly6c
-
 subset represents the 
patrolling monocyte population that is involved in active surveillance of the vasculature, where 
they are known to scavenge and eliminate cellular debris and resolve inflammation 
(20)
. 
3.1. Roles of peripheral, ‘inflammatory’ macrophages in TBI – not all macrophages are 
equal. 
Predominant expression of CCR2 on populations of inflammatory and patrolling 
monocytes has been used as a basis to distinguish them from CCR2
-
 resident microglia 
(14)
. Using 
genetic ablation of elements of the CCR2-CCL2 axis or treatment with CCR2 antagonists to 
restrict the peripheral macrophage response to TBI, various groups have identified unique roles 
for infiltrating macrophages 
(21,22)
. While loss of CCR2 signaling does not alter chronic cortical 
or hippocampal tissue loss, CCR2
-/-
 mice display improved long-term spatial memory and 
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learning 9 weeks post TBI. Interestingly, although chronic volume loss in the CA1-CA3 region 
was similar in the WT and CCR2
-/-
 cohorts, CCR2 deficiency protected CA1-CA3 neurons from 
TBI-induced death 
(21)
. Apart from being crucial for monocyte recruitment to the site of injury, 
CCR2-CCL2 signaling is critical for the egress of monocytes from the bone marrow.  A similar 
improvement in hippocampal-dependent learning and memory has been reported using the CCR2 
antagonist, CCX892 
(22)
. It is important to note that improved cognition and neuronal protection 
associated with CCR2 deficiency manifests almost 9 weeks post TBI. However, accumulation of 
CCR2
+
 macrophages is an acute inflammatory response that peaks within hours-days of the 
injury and contracts to baseline levels by 2 weeks post TBI 
(2,3)
. In contrast to the chronic effects 
of CCR2 deficiency, disrupted CCR2 signaling in CCR2
RFP/RFP
 reporter mice results in smaller 
lesion cavities with reduced axonal pathology 3 days post TBI 
(23)
. However, while TBI increases 
overall tau phosphorylation, the absence of CCR2 causes translocation of axonal pTau to 
neuronal soma. These data suggest that an acute loss of a CCR2
+
 peripheral macrophage 
response limits tissue loss and axonal damage but may aggravate development of neuro-fibrillary 
tangle pathology
 (23)
. These observations suggest two functionally distinct macrophage subsets – 
one associated with exacerbation of pathology, while another involved with prevention of intra-
neuronal aggregates of pTau. An approximate 25-50% preservation of the macrophage response 
in the CCR2
-/-
 mice or following treatment with CCX892 
(22)
, further suggests CCR2-CCL2 
independent recruitment of macrophage subpopulations following TBI.  
Lastly, studies using reporter mice to track arginase-1 (Arg1) expressing cells have 
identified Arg1
+
 and Arg1
-
 populations of infiltrating macrophages 
(24)
. Although both 
subpopulations express a mixed phenotype of pro- and anti-inflammatory markers, Arg1
+
 
macrophages preferentially upregulate genes associated with wound healing responses (CD9, 
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Spry2), regulation of tissue injury (CD36, Hmox1) and neuroprotection (Mt2, CD38), while 
Arg1
- 
macrophages show a biased upregulation of IL1β, MHC class II and Ciita indicative of a 
pro-inflammatory phenotype 
(18)
. These data raise some pertinent questions/observations that 
remain unanswered:  
1. How do various subsets of infiltrating macrophages work in concert to shape the 
evolution of TBI lesion pathology? Activation phenotypes of macrophage subsets are 
highly fluid and dynamic, thus creating a lesion microenvironment of a mixed 
monocyte/macrophage response. The heterogeneity of chemokines that recruit peripheral 
macrophages to the CNS, gives rise to the possibility of distinct signaling mechanisms 
driving infiltration of these individual macrophage subsets (Fig.1).  
2. Can activated, infiltrative macrophages drive protective responses post TBI? TBI has 
been associated with an increased risk of developing AD-like pathology, including 
aggregated tangles of pTau and subsequent dementia
(5)
. It is therefore an interesting 
speculation that there may be a distinct macrophage subpopulation that confers protection 
from development of tauopathies post TBI (Fig.1).  
3. How does an acute and/or partial ablation of the macrophage response ameliorate chronic 
cognition and memory? Data suggests that either acute ablation of a pro-inflammatory 
macrophage population and / or selective, chronic retention of a repair promoting subset 
may be critical for neuroprotection and subsequent improved cognition. 
Using the CX3CR1
GFP/+
CCR2
RFP/+
 reporter mice, Morganti et al have characterized the 
kinetics of the macrophage response following TBI 
(22)
. This study shows that while CX3CR1 
expression is limited to the CNS resident microglia following acute injury, chronic injury results 
in upregulation of CX3CR1 expression on infiltrating CCR2
+
 inflammatory
 
macrophages. These 
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CX3CR1
+
CCR2
+
 macrophages are distinct from the CX3CR1
+
CCR2
-
 resident microglia and 
persist for up to 3 weeks post TBI. However, CX3CR1
+
CCR2
+
 macrophages fail to persist in 
CNS as the injury becomes chronic, and the chronic TBI lesion remains associated with 
CX3CR1
+
CCR2
- 
cells 
(22)
. The up regulation of CX3CR1 on activated peripheral macrophages 
may allow for in-situ control of their inflammatory response via neuronal and endothelial 
CX3CL1 signaling, thereby tailoring them towards a protective phenotype. Whether myeloid 
cells associated with chronic injury lesions represent a purely chronic microglial response or are 
composed of a combination of resident microglia and CX3CR1
+
 peripheral macrophages that 
have down-regulated their CCR2 expression is currently unknown. Thus, while TBI therapies 
have targeted a pan-CCR2 response, these studies suggest that a more tailored approach that 
ablates or enhances specific macrophage subsets may be the way forward. 
3.2. Targeting brain resident microglia in TBI 
Persistent and progressive physical and/or cognitive decline as a consequence of brain 
injury has been largely attributed to sustained pro-inflammatory microglial activation 
(25)
. 
However, the precise contribution of these cells to chronic TBI pathology has remained 
controversial. Neuroimaging with the positron emission tomography (PET) ligand 
[11C](R)PK11195 (PK) has been widely used to study chronic microglial responses in TBI 
patients. PK 11195 binds to the 18kDa translocator protein (TSPO) expressed on the outer 
mitochondrial membrane and is upregulated on activated astrocytes, microglia and peripheral 
macrophages 
(4)
. TSPO ligands thus serve as a good measure of chronic gliosis. Elucidating 
microglial responses in chronic pathophysiology is further complicated by the paucity of 
differential markers to distinguish resident microglia from peripheral macrophages.  
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Given that microglia are the resident macrophage population of the CNS, their roles 
under physiological conditions and in the post injury brain are crucial for the maintenance and/or 
return to homeostasis. Two-photon imaging of microglia has revealed that these cells constantly 
survey the CNS microenvironment with highly motile processes. Through de novo process 
formation and retraction, microglia are responsible for organized scanning of CNS micro-
regions, ensuring exhaustive and repetitive surveillance of the healthy brain tissue. Unlike 
homeostatic immune surveillance, microglial response to CNS trauma results in the rapidly 
polarized extension of processes towards the injury 
(26)
. Hence, microglia are the primary innate 
immune response to injury, and also constitute the predominant macrophage population 
associated with chronic lesions. Furthermore, owing to their continuous and active inspection of 
the CNS, microglia are uniquely situated to detect and/or contribute to any pathological changes 
that are temporally and anatomically distal to the initial injury.  
In the healthy brain, microglia are maintained in a homeostatic state through a network of 
paired cell surface receptor-ligand interactions between microglia and neurons such CD200-
CD200R1 and CD47-CD127a 
(11)
. One such mechanism is through the chemokine, fractalkine 
(CX3CL1) which signals via the dedicated receptor CX3CR1. Survivors of severe TBI show 
long-term elevation in CSF levels of CX3CL1 indicating a role for fractalkine signaling in TBI 
pathophysiology 
(27)
. A microglial phenotype as a result of chronic activation/inflammation is 
associated with heightened neurotoxicity in several models of neurodegeneration (AD, PD and 
ALS) and injury. The primary disease process results in ‘microglial priming’ that is associated 
with downregulation/loss of CX3CR1 expression, and is associated with an enhanced secretion of 
inflammatory cytokines, chemokines and ROS upon lesion induced pro-inflammatory 
stimulation (Fig.1)
 (28)
. Exclusive expression of CX3CR1 by the microglia within the CNS has 
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thus made the CX3CL1-CX3CR1 axis an attractive therapeutic target for the modulation of 
microglial responses post TBI. 
3.3. CX3CR1 and its role in microglial protection of the brain 
 Studies using mice deficient in CX3CR1 have revealed an evolving role of CX3CR1 
signaling as pathology transitions from the acute to chronic stages post mild TBI. Lesions in the 
CX3CR1
-/-
 mice show increased association with cells expressing YM1 and CD206/mannose 
receptor at 7 days post injury (dpi)
(29)
. This activation phenotype, which is induced by IL-4/IL-13 
mediates clearance of cellular debris via endocytosis and phagocytosis and is involved in tissue 
repair/wound healing responses. A concomitant reduction in the numbers of CD68
+
 cells along 
with reduced iNos and IL-1β gene expression in the cortices of injured CX3CR1
-/-
 mice indicate a 
skewing of the acute lesion microenvironment towards a protective microglial phenotype 
(29,30)
. 
As the injury becomes chronic, the CX3CR1
-/-
 lesions display an increased density of iNos
+
 cells 
relative to injured WT controls. Interestingly, the chronic loss of CX3CR1 leads to increased 
abundance in the hippocampus of cells expressing the scavenger receptor ‘Macrophage Receptor 
with Collagenous Structure’ (MARCO), which is implicated in enhanced pro-inflammatory 
cytokine secretion. Although injured CX3CR1
-/-
 and WT controls showed similar absolute 
numbers of CD68
+
 cells in the hippocampus at chronic time-points, these inflammatory 
phagocytes displayed a hypertrophic morphology 
(29) 
with elevated CD11b expression, consistent 
with sustained activation which persists for up to 5 weeks post injury 
(30)
. This shift from a 
protective to an inflammatory activation status in the absence of CX3CR1 signaling correlates 
with reduced numbers of neurons in the cortex of CX3CR1
-/-
 mice with no differences in chronic 
lesion volumes. These data suggest a duality in CX3CR1 signaling where an acute, pro-
inflammatory lesion driven by CX3CR1
+
 microglia results in enhanced neurotoxicty. However, 
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chronic pro-inflammatory microglial activation is attenuated by CX3CR1, and is critical in 
limiting bystander hippocampal pathology (Fig.1).  Interestingly, unlike the worsening of chronic 
pathology in the CX3CR1
-/- 
mice, a heterozygous deletion in CX3CR1 (CX3CR1
+/-
) results in 
reduced neurodegeneration, smaller lesions and better functional recovery in comparison with 
WT controls at 80 days following moderate TBI 
(31)
. Erturk et al report that while moderate TBI 
results in a chronic lesion cavity (1 yr post TBI) that extends into the deeper regions of the 
hippocampus and thalamus, lesions in CX3CR1
+/-
 mice are restricted to the superficial cortical 
layers with a complete preservation of hippocampal structures. These data suggest that a 
complete loss of CX3CR1 (CX3CR1
-/-
) mediated control of microglial activation can drive 
chronic bystander neurotoxicity via exaggerated chronic pro-inflammatory microglial responses. 
However, a dampened CX3CR1 response (CX3CR1
+/-
) may allow for controlled microglial 
activation that not only restricts the chronic access of potentially neurotoxic peripheral immune 
lymphocytes and macrophages to the injured CNS but also protects deeper brain regions from 
neurodegeneration 
(31)
.  
How do microglia mediate long-term neuroprotection? The paradigm of CNS 
preconditioning has been studied extensively as a neuroprotective therapeutic approach 
following TBI and stroke. A broad range of stimuli, including the bacterial endotoxin 
lipopolysaccharide (LPS), is currently being tested to this end. Using a bone-marrow chimera 
approach, Chen et al generated mice with LPS-mediated TLR4 signaling restricted to the 
periphery or the CNS 
(32)
. These authors demonstrate that systemic treatment with low-dose LPS 
skews microglia towards a neuroprotective phenotype, as evidenced by enhanced expression of 
genes associated with ‘alternative activation’ that are responsible for an anti-
inflammatory/repair-promoting phenotype, characterized by the expression of Ym1, Arg1, Socs3, 
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IL4-Rα and IL1Ra with minimal expression of pro-inflammatory genes such as CCR2, iNos, and 
TNF. Furthermore, this pre-conditioning response depends upon TLR4 expression within the 
brain and remains unaltered by the absence of TLR4 on peripheral immune cells. Interestingly, 
LPS pre-conditioning resulted in increased neuronal ensheathement by activated microglia. 
Immuno-electron microscopy revealed a displacement of synaptophysin
+
 afferent synapses at the 
neuronal surface directly apposed by primed-microglia, and this correlated with significantly 
reduced lesion volumes and neuronal death following experimental cryogenic brain injury 
(23)
. 
As increased TLR-signaling downstream of TBI is a predominant acute immune response, it is 
tempting to speculate that controlled TLR-dependent microglial activation can not only alter the 
acute lesion microenvironment but may also drive chronic synaptic remodeling/modification post 
injury. 
Another possible mechanism of chronic neuroprotection is the active repair of the 
disrupted BBB
(19,33)
. Indeed, significant reduction in the frequencies of peripheral immune cells 
in CX3CR1
+/- 
injured brains relative to WT controls at 1 year post injury indicate a microglial 
contribution to chronic retention of macrophages and the re-establishment of an intact BBB 
(31)
. 
An elegant study using two-photon laser scanning microscopy has demonstrated microglial 
subsets that undergo dramatic morphological alterations forming 'honeycomb' or 'jellyfish' like 
structures following a closed skull, mild, compression induced TBI 
(33)
. An extensive network of 
honeycomb microglia lines the compromised glia limitans within an hour post injury. These 
microglia surround, and presumably protect the surviving astrocytes in the acute lesion. 
Astrocytic death associated with lesion progression corresponds with extension of non-branching 
microglial processes, also called 'jellyfish projections' towards the glia limitans. The formation of 
an uninterrupted layer of phagocytic jellyfish projections at the glia limitans denotes an effort by 
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CNS resident microglia to protect a disrupted BBB in the event of astrocytic death or 
dysfunction. The eventual death of these jellyfish microglia causes the lesion to spread and 
results in neutrophil infiltration and neuronal loss. Interestingly, while inhibition of microglial-
specific purinergic receptors P2RY12 and P2RX4 blocked formation of honeycomb and jellyfish 
structures, inhibition of P2RX7 completely blocked the neutrophil response to injury. Lastly, 
blocking connexin hemichannels to dampen astrocytic ATP production compromised purinergic 
receptor dependent formation and these microglial networks, resulting in enhanced BBB 
permeability following injury 
(33)
. Indeed, ATP mediated polarization of stable microglial 
processes towards injury lesions has been previously described as a protective mechanism that 
limits diffuse neurotoxicity 
(26)
. These data shed light on the intricate crosstalk between the 
astrocytes and microglia involved in the maintenance of BBB integrity (Fig.1).  Thus astrocytic 
ATP mediated enhancement of purinergic receptor signaling by CNS resident microglia may be 
an important factor in the formation of stable microglial networks that facilitate the re-
establishment of an intact BBB in chronic TBI. 
4. TREM2 as a modulator of pathological neuroinflammatory responses: a link 
between TBI and AD pathology. 
Post mortem analysis of brain tissue has demonstrated increased accumulation of 
extracellular deposits of Aβ and intra-neuronal NFTs, hallmarks of AD-pathology, in patients 
with TBI. While the degree of AD-like pathology varies depending on the severity and duration 
of the initial injury, the incidence of these pathological features in a significant cohort of TBI 
cases, underscores the possibility of an immunological overlap in disease mechanisms in TBI 
and AD 
(6)
. Recent Genome Wide Association Studies (GWAS) have identified crucial genetic 
variants related to innate immune signaling, including TREM2, that confer increased 
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susceptibility to development of AD and other neurodegenerative diseases and can also 
significantly alter the neurological outcome and recovery following TBI 
(34)
. Clinically, 
homozygous loss of function mutations in TREM2 have been linked to the development of Nasu-
Hakola Disease (NHD), a form of progressive, presenile dementia in which patients develop 
systemic bone cysts and progressive encephalopathy leading to mortality within the fifth decade 
of life. These studies indicate that TREM2 plays a neuro-protective role in CNS disease/injury 
(35)
. 
TREM2 is a member of the immunoglobulin (Ig) superfamily and is expressed by cells of 
the myeloid lineage, including macrophages, dendritic cells, granulocytes and osteoclasts in the 
periphery and by microglia within the CNS 
(35)
. In vitro studies have demonstrated that TREM2 
signaling dampens classical/pro-inflammatory microglial activation. shRNA mediated 
downregulation of TREM2 expression in cultured primary microglia results in increased 
secretion of TNFα and iNos, without altering expression of pro-inflammatory activation markers 
like MHC Class II, CD86 and CD11b 
(36,37)
. Subsequent studies have revealed that this occurs 
through the negative regulation of the toll-like receptor (TLR) pathway 
(38,39)
. TREM2 also 
affects phagocytosis as demonstrated by increased TREM2 expression by BV2 microglia upon 
co-culture with apoptotic neurons. Also, transfection of TREM2 into non-phagocytic Chinese 
Hamster Ovary (CHO) cells increases their phagocytic engulfment of apoptotic neurons 
(37)
.  A 
recent report by Yeh et al, suggests that TREM2 dependent uptake of Aβ-lipoprotein complexes 
results in rapid degradation of phagocytosed Aβ in-vitro, thereby providing evidence that 
TREM2 is necessary for Aβ clearance (40). 
Despite compelling in-vitro studies, elucidating the role of TREM2 in-vivo, using murine 
models of injury and/or disease have yielded conflicting results. Analysis of transcriptional 
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profiles of microglia purified from 8 month old 5XFAD;TREM2
+/+
 and 5XFAD;TREM2
-/- 
mice, 
show impaired expression of MHC Class II, CD11b, and pro-inflammatory cytokines TNFα and 
IL1β in the absence of TREM2 (41). Additionally, while the loss of TREM2 does not alter the 
capacity of microglia to phagocytose and degrade Aβ and apoptotic cells in 8 month old 5XFAD 
mice 
(41)
, TREM2 is required for the internalization of fibrillar Aβ by microglia isolated from 4 
month old 5XFAD;TREM2
+/+
 mice 
(42)
 and for the phagocytic clearance of apoptotic cells and 
myelin debris in murine models of stroke and cuprizone-induced demyelination 
(43,44)
. 
Furthermore, TREM2 signaling is critical for myeloid cell survival and proliferation in the AD 
brain, and reduces plaque-associated neurotoxicity by regulating compaction of toxic Aβ 
deposits 
(35,42)
. Thus, not only does TREM2 play varying roles in-vivo depending on the injury 
and/or disease being studied, but the downstream effects of TREM2 signaling change at different 
stages of pathology.  
Using the lateral fluid percussion injury (FPI) model, Saber et al have demonstrated 
TREM2 dependent worsening of chronic hippocampal atrophy and cognitive decline. While 
TREM2 deficiency reduces the overall recruitment of peripheral macrophages to the CNS 
following injury
 (45)
, acute lesions (3 dpi) in TREM2
-/- 
mice display an increased number of 
CD45
+
 and F4/80
+
 cells associated with injury lesions, with no differences in mRNA expression 
of TNF, IL-1β and IL-6 and lesion volumes between groups. Interestingly, injured, WT control 
animals display reduced hippocampal volumes in the ipsilateral and contralateral hemispheres as 
compared to TREM2
-/-
 mice at 120 dpi, a stage with no differences in lesion-associated, pro-
inflammatory cellular-immune responses 
(45)
. These results are unique, in that they suggest 
contrasting roles of TREM2 during acute vs. chronic injury (Fig.1). While, TREM2 may limit 
acute macrophage recruitment and dampen early inflammatory responses in the injured CNS, it 
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exacerbates neurodegeneration during chronic TBI, by mechanisms that maybe independent on 
inflammatory dysfunction.  
A similar reduction in the recruitment of a population of CD11b
+
CD45
hi
Ly6c
high
 
peripheral macrophages is associated with TREM2 deficiency in the APPPS1 and 5XFAD 
mouse models of AD 
(46)
. Reduced macrophage recruitment correlates with ameliorated Aβ 
plaque pathology in the early stages of disease. However, APPPS1; TREM2
-/-
 animals show 
increased accumulation of larger Aβ plaques in the cortex in late-stage AD, along with reduced 
expression of TNF, IL-1β and IL6 mRNA as compared to APPPS1; TREM2+/+ mice (47). It is 
important to note that TREM2 can be expressed on brain-resident microglia as well as the 
peripherally derived macrophages and the temporal profile of this cell-type specific TREM2 
response may shape lesion pathology (Fig.1). A recent elegant study using transcriptome analysis 
has suggested that attenuated CX3CR1 signaling may drive an increase in microglial-TREM2 
expression in the 5XFAD model of AD. This TREM2
+
 microglial phenotype is associated with 
an increased Aβ phagocytic capacity, and thereby is hypothesized to be protective in the context 
of amyloid clearance 
(48)
. It is an interesting hypothesis that while acute macrophage associated 
TREM2 signaling may exacerbate neuropathology; chronic microglial TREM2 is a critical 
neuroprotective response (Fig.1). Thus, how distinct cellular sources of TREM2 shape acute vs. 
chronic TBI pathophysiology remains to be investigated. Taken together, these studies are 
indicative of common TREM2-dependant mechanisms that may govern TBI mediated AD-like 
pathology in a disease-stage dependent manner.  
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5. Altered Neuroinflammation Influences Behavioral Recovery 
Inflammation in both TBI and AD has been linked to behavioral changes in multiple 
rodent models but remains controversial. However, recent studies suggest that the infiltration of 
peripheral macrophages is particularly detrimental. Mice deficient for the receptor CCR2, 
important for monocyte chemotaxis, or animals treated with CCR2 antagonists, exhibit a 
reduction in infiltrating macrophages that correlates with improved spatial learning and memory 
after TBI 
(13,21,22)
. Further studies using reporter mice for CCR2 have reported the presence of 
CCR2
+
 peripheral macrophages in areas sensitive to injury-induced pathology and inflammation, 
namely the CA3/4 region and the dentate gyrus, and depletion of these macrophages correlates 
with improved learning and cognitive behavior after TBI 
(22)
. Conversely, deficiency in CX3CR1, 
a protein important in microglial function, increases cognitive dysfunction after TBI suggesting 
that microglial activation is necessary for behavioral recovery after TBI 
(29)
. Febinger et al found 
no changes in locomotor activity or anxiety as measured through open field after brain injury in 
WT control mice. However, CX3CR1 deficiency inhibits motor and spatial learning after TBI.  
Reduced deficits in spatial working memory and spatial reference memory in injured TREM2 
deficient mice, correlate with reduced macrophage infiltration in the brain 
(45)
. A similar decrease 
in peripheral macrophage infiltration and Aβ pathology with TREM2 deficiency has also been 
reported in early disease in the APPPS1 and 5XFAD models of AD 
(42,46)
. Conversely, other 
studies have found that TREM2 upregulation ameliorates AD related behavioral deficits by 
modulating microglial function in mouse models of AD 
(49,50)
. These studies together suggest that 
while controlled microglial activation is beneficial in reducing behavioral deficits related to TBI 
and AD, the infiltration of peripheral macrophages is detrimental in AD and TBI recovery. More 
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research is necessary in this field to identify potential therapeutic targets for reducing behavioral 
deficits associated with both TBI and AD. 
6. Conclusions 
TBI induces a unique and complicated inflammatory response. A concise overview of 
this inflammatory response and its effect on behavior can be found in Figure 1. Substantial effort 
has been spent on identifying therapeutic targets that modulate the acute post-injury 
neuroinflammatory response in experimental models; however, limited translation to the clinical 
setting suggests that a multi-target therapeutic approach is needed to improve chronic outcome. 
Novel advances in the field, particularly imaging techniques and transgenic mouse models such 
as those with targeted deletion of CCR2 or CX3CR1, have proved useful in distinguishing 
microglia and macrophages in brain injury and AD pathophysiology. These studies suggest that 
microglia and macrophages maintain the ability to be both beneficial and detrimental in disease 
pathogenesis and their timing of reactivity is critical in mediating outcome. Future studies that 
consider the cell specific response of microglia and macrophages to TBI will be necessary in 
improving post-injury recovery. Recent, genetic-based studies have suggested that inflammation, 
particularly the peripheral macrophage response, may be the underlying link between brain 
injury and the progression of AD pathology. Thus, determining the role of genetic influences and 
the progression of neurodegeneration via novel targets such as TREM2 will also be a key 
component in effectively managing outcome after TBI.  
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Figure 1. Lesion pathophysiology following TBI is governed by the dynamics between 
neurotoxic and neuroprotective/regenerative immune responses. Within hours of TBI (top 
panel), CNS resident microglia and astrocytes are activated as a consequence of the physical 
injury and in response to DAMPs released by apoptotic/necrotic cells, along with serum proteins 
released in the CNS from a disrupted BBB.  Neuroprotective gliosis that functions to contain 
injury lesion begins within minutes following injury (top panel), continues to evolve and persists 
for months/years after initial injury (middle-bottom panel). These neuroprotective glial responses 
facilitate the stabilization, repair and re-establishment of the BBB and release chemokines and 
trophic factors that support recruitment of precursor populations and their in-situ differentiation. 
Furthermore activated microglia can skew astroglial responses towards a neurotoxic or a 
neuroprotective phenotype. Acute glial activation results in the secretion of chemokines and the 
recruitment of peripheral immune cells, namely neutrophils and populations of CCR2
+
 and 
CCR2
-
 macrophages. Macrophage recruitment, which peaks within 2-3 days post injury, results 
in the accumulation of neurotoxic (TREM2
+
 and Arginase1
-
) as well as neuroprotective 
(Arginase1
+
) populations (middle panel). Phagocytic clearance of apoptotic cells and other debris 
by TREM2
+
 macrophages and microglia may further drive their neurotoxic, pro-inflammatory 
activation. While CNS resident microglia are the primary CX3CR1
+
 population in the lesion, 
infiltrating macrophages upregulate CX3CR1 expression in-situ (middle panel). This population 
of CX3CR1
+
 microglia and macrophages can be modulated via CX3CL1 mediated neuronal 
signaling and may represent a neuroprotective response that can allow for controlled 
phagocytosis and removal of cellular and myelin debris without eliciting bystander immune-
pathology (middle-bottom panels). Accumulation of extracellular deposits of amyloid-β (Aβ) and 
intra-neuronal neurofibrillary tangles (NFTs) of hyperphosphorylated tau (pTau) as lesions 
  
28 
become chronic are accompanied by plaque-associated gliosis that may be pro- and/or anti-
inflammatory (bottom panel). In contrast to the acute neurotoxic effects of TREM2 (middle 
panel), prolonged TREM2 expression on microglia and macrophages may be critical for their 
survival in the chronic lesion microenvironment. Additionally, sustained upregulation of TREM2 
expression on plaque associated microglia and macrophages at this stage may be critical for the 
phagocytic removal of Aβ and the compaction of Aβ plaques, thereby driving neuroprotective 
responses (bottom panel).   
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Highlights: 
 Blood-brain-barrier disruption facilitates influx of peripheral cells after TBI 
 Peripheral macrophages and resident microglia have distinct roles after TBI 
 Macrophage sub-populations possess both beneficial and detrimental properties  
 CX3CR1 deletion shows time dependent neuroprotective properties of microglia 
 CCR2 and TREM2 deletion reduces monocytes and improves behavioral recovery  
 
  
INFLAMMATORY GLIAL OUTCOMES BEHAVIORAL AND PATHOLOGICAL  OUTCOMES 
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1. Microglial and Astroglial activation due to serum proteins in the brain as a result of the 
physical disruption of the BBB 
2. Release of pro-inflammatory mediators (IFNγ, ROS, TNF, IL1β etc) in response to 
DAMPs (DNA, RNA, ATP) released by necrotic and apoptotic cells 
3. Increased secretion of chemokines (CCL2, CCL5, CXCL1, CXCL2, CXCL8 etc ) and 
recruitment of inflammatory immune cells  
• Neutrophils : ROS production leading to cellular /neuro-toxicity 
• Macrophages : Neurotoxic CCR2+TREM2+, other CCR2+TREM2- subpopulations 
4. Increased phagocytosis and clearance of cellular debris by microglia and macrophages 
5. Increased gliosis to clear apoptotic cells promote BBB repair and contain the injury 
lesion 
6. Active synaptic stripping by pro-inflammatory astrocytes and microglia  
 
 
 
1. Heightened chemokine synthesis by astrocytes and microglia resulting in increased 
infiltration of macrophage  subsets. In-situ macrophage polarization. 
• CCR2+TREM2+ macrophages (neurotoxic), Arginase1- (increased pro-inflammatory 
signaling)  
• CCR2+TREM2- macrophages (prevent neuronal accumulation of NFTs), Arginase1+ 
macrophages (increased anti-inflammatory signaling), CX3CR1
+ macrophages 
(possibly neuroprotective) 
2. Early loss/down-regulation of CX3CR1 on microglia drives protective responses 
(increased phagocytosis of cellular and myelin debris (via increased TREM2), increased 
IL-10, Arginase1 etc. Active myelin stripping). Sustained loss of CX3CR1 signaling 
drives increased pro-inflammatory activation (may result in spread of inflammatory 
lesion). 
3. Pro-inflammatory microglia drive neurotoxic astroglial responses, resulting in aberrant 
synaptosome engulfment, synaptic stripping, glutamate and excitotoxic neuronal death 
4. Anti-inflammatory glial responses resulting in synaptogenesis, recruitment and 
differentiation of glial precursors, and remyelination/repair  
 
 
 
1. Re-establishment of a stable BBB, but possible leaky barriers that allow for sustained 
infiltration of the CNS by peripheral immune cells.  
• Passive infiltration or active recruitment due to sustained/chronic chemokine 
expression by glial cells in the injured CNS? 
2. Extracellular deposition of Aβ plaques resulting in accumulation of microglia, 
macrophages and astrocytes to plaque vicinity. Increase intra-neuronal NFTs. 
• Varied activation phenotypes of plaque associated immune cells in a region/plaque 
specific manner? Plaque associated immune response can be both pro- and/or anti-
inflammatory 
3. Retention and/or survival (TREM2 dependent) of a heterogeneous population of 
peripheral macrophages.  
4. Heterogeneous activation phenotypes of resident microglia that may drive a mixed 
astrocyte activation. Chronic expression of TREM2 on resident microglia?  
5. Reactive astrogliosis driven stabilization of the BBB (neuroprotective) and scar-
formation that inhibits nerve regeneration, drives ROS/S100B/glutamate etc. mediated  
neurodegeneration 
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1. Loss of consciousness immediately following 
injury 
• Edema, axonal shearing due to mechanical 
impact of the injury 
2. Neuromotor deficits manifest within hours post 
injury, which can last for days to weeks post 
injury. 
• Limb suspension, inability to stand on 
inclined or vertical plane in rodent models 
 
1. Decrease in hippocampal dependent spatial 
memory, motor learning and cognitive function. 
Rescued by a loss of CCR2+ inflammatory 
macrophages in rodent models 
2. Increase in anxiety-like behavior. Rescued by loss 
of TREM2+ macrophage responses in rodent 
models 
• Smaller acute lesions, but no difference in 
chronic (~ 9 weeks post injury) hippocampal 
volumes in the absence of CCR2+ 
macrophage responses. 
• No differences in lesion volumes with 
complete loss of CX3CR1 signaling on 
microglia (~ 5 weeks post injury) 
 
 
1. Deficits in spatial learning and memory in rodent 
models, ~ 3-4 months post injury. Rescued by a 
deficiency of TREM2+ macrophage responses. 
• Reduced hippocampal lesion volumes at ~ 3-
4 months post injury in the absence of 
TREM2+ responses 
• Partial loss of CX3CR1 (CX3CR1
+/-) 
signaling results in significantly reduced 
volumes of hippocampal and cortical lesions 
1 year post injury 
2. Persisting cognitive deficits (memory loss, 
confusion) seen in clinical TBI patients.   
 
Survival factors, MMPs 
